GLP-1 Medications Complete Guide 2026

1. What is a GLP-1 medication?

GLP-1 (glucagon-like peptide-1) medications are a class of drugs that mimic a natural gut hormone called GLP-1. The body releases GLP-1 after eating; it signals the pancreas to release insulin, suppresses glucagon (which raises blood sugar), slows gastric emptying, and acts on appetite centers in the brain. Pharmaceutical GLP-1 agonists are engineered to resist breakdown by the enzyme DPP-4 that normally degrades natural GLP-1 within minutes — letting the drug last hours (daily injections) or days (weekly injections).

The first GLP-1 drug, exenatide (Byetta), was FDA-approved in 2005 for type 2 diabetes. The class expanded slowly through the 2010s (liraglutide 2010, dulaglutide 2014, semaglutide 2017). The inflection point came with Wegovy's 2021 weight-loss approval and Zepbound's 2023 approval, which together pushed GLP-1s from a diabetes-specialty class into one of the largest drug categories in the US by sales.

2. How GLP-1s work in the body

GLP-1 receptors are present on pancreatic beta cells, gastric smooth muscle, vagal nerves, and multiple brain regions including the hypothalamus and brainstem. When a GLP-1 drug binds these receptors, four major effects occur:

1. Insulin release— Pancreatic beta cells secrete insulin in a glucose-dependent manner. This means GLP-1s lower blood sugar primarily when it's elevated, reducing hypoglycemia risk compared to sulfonylureas or insulin alone.
2. Glucagon suppression — Glucagon (which raises blood sugar by releasing liver glycogen) drops, contributing to glycemic control.
3. Delayed gastric emptying — Food remains in the stomach longer, prolonging satiety. This is the primary mechanism behind appetite reduction and explains why nausea is the most common side effect (especially during titration).
4. Central appetite suppression— Direct action on hypothalamic and brainstem centers reduces hunger drive and food reward signaling. Patients often describe “food noise” (intrusive thoughts about eating) quieting on GLP-1s.

Tirzepatide adds a second receptor: GIP (glucose-dependent insulinotropic polypeptide). The dual GIP/GLP-1 mechanism is believed to drive its superior weight-loss outcomes vs semaglutide, though the exact contribution of each receptor is still being characterized.

3. All 8 FDA-approved GLP-1s (full comparison)

As of mid-2026, eight GLP-1 medications are FDA-approved in the United States. Five contain semaglutide or tirzepatide (the modern, weekly-dosed drugs); three are older daily or weekly formulations.

4. FDA-approved uses by indication

GLP-1 indications have expanded significantly. As of mid-2026:

• Type 2 diabetes: Ozempic, Mounjaro, Rybelsus, Trulicity, Bydureon, Byetta
• Chronic weight management: Wegovy (ages 12+), Zepbound, Saxenda (ages 12+)
• Cardiovascular event reduction: Wegovy (SELECT trial), Ozempic (SUSTAIN-6), Trulicity (REWIND), Victoza (LEADER)
• Obstructive sleep apnea (moderate-to-severe, with obesity): Zepbound (SURMOUNT-OSA)
• Chronic kidney disease (T2D-related): Ozempic — added based on FLOW trial

Off-label use is common: Ozempic and Mounjaro are widely prescribed for weight loss despite only having diabetes indications. Off-label prescribing is legal but can affect insurance coverage decisions.

5. Cost landscape: brand, savings programs, compounded

GLP-1 pricing in 2026 sits in three tiers:

1. Brand list price ($998-1,349/month): Wegovy $1,349; Saxenda $1,349; Mounjaro $1,086; Zepbound $1,086; Ozempic $998; Rybelsus $998. These are wholesale acquisition costs (WAC); actual pharmacy prices include retailer markup.
2. Manufacturer direct programs ($349-499/month): Eli Lilly's LillyDirect program offers Zepbound single-dose vials at $349 (2.5mg starter) up to $499 (15mg maintenance). NovoCare offers savings cards for commercially-insured Wegovy patients ($0-25/month with coverage; up to ~$650/month if no coverage). Eligibility excludes Medicare, Medicaid, and uninsured.
3. Compounded ($150-300/month): State-licensed compounding pharmacies prepare semaglutide or tirzepatide under prescription. NOT FDA-approved as finished products. Legal basis narrowed after FDA resolved the GLP-1 shortage in February 2025. Most major telehealth providers now route patients toward FDA-approved options when feasible.

For the most current pricing across telehealth providers, see our 12-provider comparison which is updated weekly.

6. Insurance coverage: commercial, Medicare, Medicaid

GLP-1 coverage is fragmented across payer types:

Commercial insurance

Coverage varies by employer plan. Most plans cover GLP-1s for diabetes; weight-management coverage is less common but expanding. Many plans require prior authorization with documented BMI, comorbidity, or failed lifestyle intervention. Some employers explicitly exclude weight-loss drugs from coverage; check your plan's formulary.

Medicare

Medicare Part D cannot cover drugs used for weight loss alone, per MMA 2003 §1860D-2(e)(2)(A) — this is statutory, not a plan-level choice. However:

• Diabetes drugs (Ozempic, Mounjaro, Rybelsus, Trulicity): generally covered
• Wegovy: covered when prescribed for established cardiovascular disease (SELECT-trial expansion)
• Saxenda, Zepbound (weight indications): NOT covered by Part D

Active legislation (Treat and Reduce Obesity Act, TROA) has been proposed multiple times to allow weight-management coverage; none has passed as of mid-2026.

Medicaid

Medicaid coverage of GLP-1s for weight loss is state-by-state. About 13 states explicitly cover GLP-1s for obesity as of 2026; most cover diabetes indications uniformly. See our state-by-state pages for current coverage status.

7. Side effects + how to manage them

The most common GLP-1 side effects are gastrointestinal, typically peaking during dose escalation and improving with continued use:

• Nausea (30-50%) — Smaller meals, avoid greasy/fried foods, ginger may help. Full management guide.
• Diarrhea (10-15%) — Hydration, BRAT diet during flares. Full guide.
• Constipation (8-12%) — Fiber + fluid + movement. Full guide.
• Vomiting (5-10%) — Watch for dehydration; if persistent >24h call prescriber
• Fatigue (5-10%) — Often reflects undereating; protein-first meals help. Full guide.

Uncommon but serious adverse events include pancreatitis (<1%), gallbladder disease, and (with rapid weight loss) worsening diabetic retinopathy in patients with pre-existing retinopathy. The FDA boxed warning addresses theoretical medullary thyroid carcinoma risk based on rodent data.

8. Who should NOT take a GLP-1

Absolute contraindications (per FDA labels):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Hypersensitivity to the active ingredient
• Pregnancy or planning pregnancy (lack of safety data + animal-study concerns)

Use with caution (discuss with prescriber):

• History of pancreatitis
• Severe gastroparesis or other GI motility disorders
• History of diabetic retinopathy (rapid A1C lowering may worsen)
• Active gallbladder disease
• Concurrent use of insulin or sulfonylureas (hypoglycemia risk; dose adjustment likely needed)

9. Starting a GLP-1: what to expect week-by-week

All injectable GLP-1s use a stepped titration to minimize GI side effects. For Wegovy, the standard schedule is:

• Weeks 1-4: 0.25mg weekly
• Weeks 5-8: 0.5mg weekly
• Weeks 9-12: 1.0mg weekly
• Weeks 13-16: 1.7mg weekly
• Week 17+: 2.4mg weekly (maintenance)

For Zepbound: 2.5 → 5 → 7.5 → 10 → 12.5 → 15mg (each step 4 weeks minimum). Many patients stay at lower maintenance doses if they achieve target weight loss earlier.

What patients commonly experience: peak nausea in weeks 2-4 of each new dose; appetite reduction noticeable within the first week; weight loss kicks in by weeks 4-8; mood and energy typically stable but may dip if undereating; sleep often improves with weight loss.

10. What happens when you stop

In STEP-4 (semaglutide withdrawal), patients who stopped Wegovy after 20 weeks of treatment regained roughly two-thirds of lost weight by week 68. SURMOUNT-4 (tirzepatide) showed similar regain. The pharmacologic effect ends when the drug clears (1-2 weeks for semaglutide; longer for tirzepatide), and the original appetite and gastric-emptying signals return. Most patients need ongoing therapy for sustained outcomes.

This framing — chronic therapy similar to statins or blood pressure medications — is now standard guidance from endocrinology and obesity-medicine societies. Some patients successfully maintain weight loss on a lower-dose maintenance schedule.

11. The compounded GLP-1 landscape in 2026

During the 2023-2024 FDA shortage of semaglutide and tirzepatide, the FDA legally permitted mass compounding under 503A and 503B pharmacy rules. This created a multi-billion-dollar telehealth industry offering compounded versions at $150-300/month.

The FDA resolved the semaglutide shortage in February 2025 and tirzepatide in December 2024. The legal basis for new large-volume compounding narrowed substantially. The FDA has been clear that compounded versions are NOT FDA-approved as finished products, and Eli Lilly has actively challenged compounded tirzepatide marketing in court.

Where things stand mid-2026: existing patients on compounded regimens are still being served by smaller compounders; major telehealth providers (Hims, Sequence, Mochi) are increasingly routing new patients to LillyDirect Zepbound or Wegovy where covered. Read our compounded semaglutide deep-dive for the full legal + safety picture.

12. Where the class is heading (pipeline)

The GLP-1 pipeline is unusually deep:

• Oral tirzepatide: Eli Lilly's orforglipron is in Phase 3 — could be the first effective oral non-peptide GLP-1.
• Triple agonists (GLP-1 + GIP + glucagon): Eli Lilly's retatrutide showed ~24% weight loss in Phase 2 — potentially higher than tirzepatide.
• Long-acting (monthly) GLP-1s: Multiple candidates in early-phase trials.
• Combination with muscle-preserving agents: Trials exploring GLP-1 + bimagrumab or apitegromab to preserve lean mass during weight loss.
• Generic semaglutide: Patent expiry in some markets is 2026-2031 depending on jurisdiction; US generic timing uncertain.

13. Frequently asked questions

What is a GLP-1 medication?

GLP-1 (glucagon-like peptide-1) medications are a class of drugs that mimic a natural gut hormone to lower blood sugar, slow gastric emptying, and reduce appetite. The class includes semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), and exenatide. FDA-approved uses include type 2 diabetes, chronic weight management, cardiovascular event reduction, and obstructive sleep apnea.

Which GLP-1 medication produces the most weight loss?

In FDA-pivotal trials, Zepbound (tirzepatide 15mg) achieved the highest weight loss — 22.5% over 72 weeks in SURMOUNT-1. Wegovy (semaglutide 2.4mg) was next at 14.9% over 68 weeks in STEP-1. Saxenda (liraglutide 3mg) achieved 7.4% over 56 weeks. Individual results vary; trial outcomes occurred alongside lifestyle modification.

How much do GLP-1 medications cost without insurance?

List prices range from $998-1,349 per month for FDA-approved brand GLP-1s as of mid-2026. Wegovy and Saxenda list at $1,349/month; Mounjaro and Zepbound at $1,086/month; Ozempic and Rybelsus at $998/month. Eli Lilly's LillyDirect program offers Zepbound single-dose vials at $349-499/month. Compounded semaglutide via state-licensed pharmacies costs $150-300/month but is NOT FDA-approved as a finished product.

Are GLP-1 medications safe long-term?

Long-term safety data exist for semaglutide (10+ years cumulative trial follow-up) and liraglutide (15+ years). Both show favorable cardiovascular outcomes. The FDA boxed warning for all GLP-1s addresses a theoretical risk of medullary thyroid carcinoma based on rodent studies — humans have lower thyroid C-cell density and the risk has not been confirmed in human trials. Pancreatitis is a documented uncommon adverse event (<1% in trials). Long-term tirzepatide data are still accumulating.

What happens if I stop taking a GLP-1 medication?

In the STEP-4 trial (semaglutide withdrawal), patients who stopped Wegovy after 20 weeks regained two-thirds of lost weight by week 68. SURMOUNT-4 showed similar regain after stopping tirzepatide. The medications work by ongoing pharmacologic action — when discontinued, appetite and gastric-emptying signals return to baseline. Most patients require ongoing therapy for sustained weight loss, similar to other chronic disease medications.

Are compounded GLP-1 medications safe?

Compounded GLP-1s are NOT FDA-approved as finished products. They use the same active ingredients but the FDA does not review the specific compounded formulation for safety, potency, or quality. The legal basis for mass compounding narrowed after FDA resolved the GLP-1 shortage in early 2025. Patients considering compounded versions should verify the pharmacy is state-licensed, require a real prescription, and avoid "salt" forms (semaglutide sodium) which the FDA has flagged as unapproved.

Does Medicare cover GLP-1 medications for weight loss?

Medicare Part D is statutorily prohibited from covering drugs used for weight loss alone (MMA 2003, §1860D-2(e)(2)(A)). This applies to Wegovy, Zepbound, and Saxenda when prescribed for weight loss. However, Ozempic, Mounjaro, Trulicity, and Rybelsus may be covered when prescribed for type 2 diabetes, and Wegovy is covered when prescribed for established cardiovascular disease (under the 2024 SELECT-trial indication expansion).

• Editorial board reviewed
• CC BY 4.0 data
• FDA-source citations
• Affiliate disclosed

This guide is editorial and does not constitute medical advice. GLP1Zoom is affiliate-disclosed: we earn commission when readers sign up with partner providers via our links. Editorial reviewers are paid flat fees, never commission. Always consult your prescriber before starting, changing, or stopping any medication. Full disclaimer· Affiliate disclosure· Editorial policy.